{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T05:51:07Z","timestamp":1794289867737,"version":"4.9.0"},"reference-count":92,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T00:00:00Z","timestamp":1687046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T00:00:00Z","timestamp":1687046400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100013671","name":"Sun Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013671","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s12325-023-02568-0","type":"journal-article","created":{"date-parts":[[2023,6,18]],"date-time":"2023-06-18T07:01:12Z","timestamp":1687071672000},"page":"3410-3433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review"],"prefix":"10.1007","volume":"40","author":[{"given":"Andrew","family":"Blauvelt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Chiricozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin D.","family":"Ehst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark G.","family":"Lebwohl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,6,18]]},"reference":[{"issue":"8","key":"2568_CR1","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1001\/jamadermatol.2021.2007","volume":"157","author":"AW Armstrong","year":"2021","unstructured":"Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis prevalence in adults in the United States. JAMA Dermatol. 2021;157(8):940\u20136.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"2568_CR2","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jaad.2016.07.064","volume":"76","author":"J Takeshita","year":"2017","unstructured":"Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377\u201390.","journal-title":"J Am Acad Dermatol"},{"issue":"10281","key":"2568_CR3","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","volume":"397","author":"CEM Griffiths","year":"2021","unstructured":"Griffiths CEM, Armstrong AW, Gudjonsson JE, Barker J. Psoriasis. Lancet. 2021;397(10281):1301\u201315.","journal-title":"Lancet"},{"issue":"19","key":"2568_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1001\/jama.2020.4006","volume":"323","author":"AW Armstrong","year":"2020","unstructured":"Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a review. JAMA. 2020;323(19):1945\u201360.","journal-title":"JAMA"},{"issue":"9997","key":"2568_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","volume":"386","author":"WH Boehncke","year":"2015","unstructured":"Boehncke WH, Schon MP. Psoriasis. Lancet. 2015;386(9997):983\u201394.","journal-title":"Lancet"},{"issue":"1","key":"2568_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.jaad.2019.08.026","volume":"82","author":"B Strober","year":"2020","unstructured":"Strober B, Ryan C, van de Kerkhof P, et al. Recategorization of psoriasis severity: Delphi consensus from the International Psoriasis Council. J Am Acad Dermatol. 2020;82(1):117\u201322.","journal-title":"J Am Acad Dermatol"},{"issue":"18","key":"2568_CR7","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMra041320","volume":"352","author":"MP Schon","year":"2005","unstructured":"Schon MP, Boehncke WH. Psoriasis. N Engl J Med. 2005;352(18):1899\u2013912.","journal-title":"N Engl J Med"},{"issue":"12","key":"2568_CR8","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1080\/14712598.2022.2100219","volume":"22","author":"WH Boehncke","year":"2022","unstructured":"Boehncke WH, Brembilla NC. Pathogenesis-oriented therapy of psoriasis using biologics. Expert Opin Biol Ther. 2022;22(12):1463\u201373.","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"2568_CR9","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2017.1292137","volume":"13","author":"L Puig","year":"2017","unstructured":"Puig L. The role of IL 23 in the treatment of psoriasis. Expert Rev Clin Immunol. 2017;13(6):525\u201334.","journal-title":"Expert Rev Clin Immunol"},{"key":"2568_CR10","unstructured":"Janssen Biotech. STELARA (ustekinumab) [package insert]. Horsham: Janssen Biotech. 2022. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/STELARA-pi.pdf. Accessed June 2023."},{"issue":"12","key":"2568_CR11","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1080\/14712598.2022.2089020","volume":"22","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Fabbrocini G, Camela E. Treating psoriasis in the elderly: biologics and small molecules. Expert Opin Biol Ther. 2022;22(12):1503\u201320.","journal-title":"Expert Opin Biol Ther"},{"key":"2568_CR12","unstructured":"AbbVie. HUMIRA (adalimumab) [package insert]. 2021. North Chicago: AbbVie. https:\/\/www.rxabbvie.com\/pdf\/humira.pdf. Accessed June 2023."},{"key":"2568_CR13","unstructured":"UCB. CIMZIA (certolizumab pegol) [package insert]. 2019. Georgia: UCB. https:\/\/www.cimzia.com\/themes\/custom\/cimzia\/docs\/CIMZIA_full_prescribing_information.pdf. Accessed June 2023."},{"key":"2568_CR14","unstructured":"Janssen Biotech. REMICADE (infliximab) [package insert]. 2021. Horsham: Janssen Biotech. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/REMICADE-pi.pdf. Accessed June 2023."},{"key":"2568_CR15","unstructured":"Amgen. ENBREL (etanercept) [package insert]. 2022. Thousand Oaks: Amgen. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Enbrel\/enbrel_pi.pdf. Accessed June 2023."},{"key":"2568_CR16","unstructured":"Bausch Health. SILIQ (brodalumab) [package insert]. 2020. Bridgewater: Bristol-Myers Squibb. https:\/\/pi.bauschhealth.com\/globalassets\/BHC\/PI\/Siliq-pi.pdf. Accessed June 2023."},{"key":"2568_CR17","unstructured":"Eli Lilly. TALTZ (ixekizumab) [package insert]. 2022. Indianapolis: Eli Lilly. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/125521s000lbl.pdf. Accessed June 2023."},{"key":"2568_CR18","unstructured":"Novartis. COSENTYX (secukinumab) [package insert]. 2021 East Hanover: Novartis. https:\/\/www.novartis.com\/us-en\/sites\/novartis_us\/files\/cosentyx.pdf. Accessed June 2023."},{"issue":"12","key":"2568_CR19","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1517\/14712598.2013.848194","volume":"13","author":"C De Simone","year":"2013","unstructured":"De Simone C, Amerio P, Amoruso G, et al. Immunogenicity of anti-TNFalpha therapy in psoriasis: a clinical issue? Expert Opin Biol Ther. 2013;13(12):1673\u201382.","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"2568_CR20","doi-asserted-by":"publisher","first-page":"1690","DOI":"10.3390\/ijms21051690","volume":"21","author":"M Kamata","year":"2020","unstructured":"Kamata M, Tada Y. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690.","journal-title":"Int J Mol Sci"},{"key":"2568_CR21","unstructured":"Janssen Biotech. TREMFYA (guselkumab) [package insert]. 2020. Horsham: Janssen Biotech. https:\/\/www.janssenlabels.com\/package-insert\/product-monograph\/prescribing-information\/TREMFYA-pi.pdf. Accessed June 2023."},{"key":"2568_CR22","unstructured":"AbbVie. SKYRIZI (risankizumab-rzaa) [package insert]. 2022. North Chicago: AbbVie. https:\/\/www.rxabbvie.com\/pdf\/skyrizi_pi.pdf. Accessed June 2023."},{"key":"2568_CR23","unstructured":"Sun Pharma Global. ILUMYA\u00ae (tildrakizumab-asmn) [package insert]. 2020. Sharjah: Sun Pharma Global. https:\/\/www.ilumya.com\/pdfs\/Sun_Pharma_ILUMYA_US_Prescribing_Information.pdf. Accessed June 2023."},{"issue":"3","key":"2568_CR24","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","volume":"76","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Griffiths CE, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405\u201317.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"2568_CR25","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jaad.2016.11.042","volume":"76","author":"K Reich","year":"2017","unstructured":"Reich K, Armstrong AW, Foley P, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017;76(3):418\u201331.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2568_CR26","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1111\/bjd.15750","volume":"178","author":"RG Langley","year":"2018","unstructured":"Langley RG, Tsai TF, Flavin S, et al. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Br J Dermatol. 2018;178(1):114\u201323.","journal-title":"Br J Dermatol"},{"issue":"10201","key":"2568_CR27","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/S0140-6736(19)31773-8","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Armstrong AW, Langley RG, et al. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Lancet. 2019;394(10201):831\u20139.","journal-title":"Lancet"},{"issue":"5","key":"2568_CR28","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1111\/bjd.17454","volume":"180","author":"K Reich","year":"2019","unstructured":"Reich K, Papp KA, Armstrong AW, et al. Safety of guselkumab in patients with moderate-to-severe psoriasis treated through 100 weeks: a pooled analysis from the randomized VOYAGE 1 and VOYAGE 2 studies. Br J Dermatol. 2019;180(5):1039\u201349.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2568_CR29","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.jaad.2019.11.040","volume":"82","author":"K Reich","year":"2020","unstructured":"Reich K, Griffiths CEM, Gordon KB, et al. Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2020;82(4):936\u201345.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2568_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1016\/j.jaad.2021.11.004","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Tsai TF, Langley RG, et al. Consistent safety profile with up to 5 years of continuous treatment with guselkumab: pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis. J Am Acad Dermatol. 2022;86(4):827\u201334.","journal-title":"J Am Acad Dermatol"},{"issue":"23","key":"2568_CR31","first-page":"00524","volume":"S0190\u20139622","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Lebwohl M, Langley RG, et al. Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials. J Am Acad Dermatol. 2023;S0190\u20139622(23):00524\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"2568_CR32","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1111\/jdv.16460","volume":"34","author":"L Puig","year":"2020","unstructured":"Puig L, Tsai TF, Bhutani T, et al. Safety in moderate-to-severe plaque psoriasis patients with latent tuberculosis treated with guselkumab and anti-tuberculosis treatments concomitantly: results from pooled phase 3 VOYAGE 1 & VOYAGE 2 trials. J Eur Acad Dermatol Venereol. 2020;34(8):1744\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"2568_CR33","doi-asserted-by":"publisher","first-page":"855","DOI":"10.36849\/JDD.6216","volume":"20","author":"P Foley","year":"2021","unstructured":"Foley P, Reich K, Blauvelt A, et al. Serious gastrointestinal-related adverse events among psoriasis patients treated with guselkumab in VOYAGE 1 and VOYAGE 2. J Drugs Dermatol. 2021;20(8):855\u201360.","journal-title":"J Drugs Dermatol"},{"issue":"12","key":"2568_CR34","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1111\/1346-8138.15109","volume":"46","author":"K Reich","year":"2019","unstructured":"Reich K, Song M, Li S, et al. Consistent responses with guselkumab treatment in Asian and non-Asian patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2. J Dermatol. 2019;46(12):1141\u201352.","journal-title":"J Dermatol"},{"issue":"1","key":"2568_CR35","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/09546634.2020.1770174","volume":"33","author":"SW Youn","year":"2022","unstructured":"Youn SW, Yu DY, Kim TY, et al. Efficacy and safety of guselkumab compared with placebo and adalimumab in Korean patients with moderate-to-severe psoriasis: Post-hoc analysis from the phase III, double-blind, placebo- and active-comparator\u2013controlled VOYAGE 1\/2 trials. J Dermatolog Treat. 2022;33(1):535\u201341.","journal-title":"J Dermatolog Treat"},{"issue":"10","key":"2568_CR36","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1001\/jamadermatol.2019.1394","volume":"155","author":"T Terui","year":"2019","unstructured":"Terui T, Kobayashi S, Okubo Y, et al. Efficacy and safety of guselkumab in Japanese patients with palmoplantar pustulosis: a phase 3 randomized clinical trial. JAMA Dermatol. 2019;155(10):1153\u201361.","journal-title":"JAMA Dermatol"},{"key":"2568_CR37","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad081","author":"A Blauvelt","year":"2023","unstructured":"Blauvelt A, Tha\u00e7i D, Papp KA, et al. Safety of guselkumab in patients with psoriasis with a history of malignancy: 5-year results from the VOYAGE 1 and VOYAGE 2 trials. Br J Dermatol. 2023. https:\/\/doi.org\/10.1093\/bjd\/ljad081.","journal-title":"Br J Dermatol"},{"issue":"5","key":"2568_CR38","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1080\/09546634.2022.2036674","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Guselkumab is efficacious and safe in psoriasis patients who failed anti-IL17: a 52-week real-life study. J Dermatolog Treat. 2022;33(5):2560\u20134.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"2568_CR39","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14673","volume":"34","author":"A Ruggiero","year":"2021","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Megna M. Efficacy and safety of guselkumab in psoriasis patients who failed ustekinumab and\/or anti-interleukin-17 treatment: a real-life 52-week retrospective study. Dermatol Ther. 2021;34(1): e14673.","journal-title":"Dermatol Ther"},{"issue":"2","key":"2568_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14798","volume":"34","author":"R Ruiz-Villaverde","year":"2021","unstructured":"Ruiz-Villaverde R, Rodriguez-Fernandez-Freire L, Armario-Hita JC, P\u00e9rez-Gil A, Gal\u00e1n-Guti\u00e9rrez M. Guselkumab: mid-term effectiveness, drug survival, and safety in real clinical practice. Dermatol Ther. 2021;34(2): e14798.","journal-title":"Dermatol Ther"},{"issue":"3","key":"2568_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13344","volume":"33","author":"L Rodriguez-Fernandez-Freire","year":"2020","unstructured":"Rodriguez-Fernandez-Freire L, Gal\u00e1n-Guti\u00e9rrez M, Armario-Hita JC, P\u00e9rez-Gil A, Ruiz-Villaverde R. Guselkumab: short-term effectiveness and safety in real clinical practice. Dermatol Ther. 2020;33(3): e13344.","journal-title":"Dermatol Ther"},{"issue":"6","key":"2568_CR42","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13964","volume":"33","author":"I Snast","year":"2020","unstructured":"Snast I, Sherman S, Holzman R, Hodak E, Pavlovsky L. Real-life experience of guselkumab in patients with psoriasis. Dermatol Ther. 2020;33(6): e13964.","journal-title":"Dermatol Ther"},{"issue":"3","key":"2568_CR43","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1111\/ced.14979","volume":"47","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Fabbrocini G, Cinelli E, Ocampo Garza SS, Camela E, Megna M. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2022;47(3):561\u20137.","journal-title":"Clin Exp Dermatol"},{"issue":"12","key":"2568_CR44","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1080\/14712598.2022.2090835","volume":"22","author":"M Galluzzo","year":"2022","unstructured":"Galluzzo M, Talamonti M, Bernardini N, et al. Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year. Expert Opin Biol Ther. 2022;22(12):1585\u201392.","journal-title":"Expert Opin Biol Ther"},{"issue":"9","key":"2568_CR45","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1111\/jdv.18218","volume":"36","author":"S Gerdes","year":"2022","unstructured":"Gerdes S, Asadullah K, Hoffmann M, et al. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. J Eur Acad Dermatol Venereol. 2022;36(9):1568\u201377.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"12","key":"2568_CR46","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1111\/1346-8138.16128","volume":"48","author":"S Gerdes","year":"2021","unstructured":"Gerdes S, Br\u00e4u B, Hoffmann M, et al. Real-world effectiveness of guselkumab in patients with psoriasis: health-related quality of life and efficacy data from the noninterventional, prospective, German multicenter PERSIST trial. J Dermatol. 2021;48(12):1854\u201362.","journal-title":"J Dermatol"},{"issue":"8","key":"2568_CR47","doi-asserted-by":"publisher","first-page":"864","DOI":"10.36849\/JDD.6962","volume":"21","author":"D Marletta","year":"2022","unstructured":"Marletta D, Murgia G, Cattaneo A, Carrera C, Marzano A. Single-centre real-life experience of guselkumab in patients with moderate-to-severe plaque psoriasis. J Drugs Dermatol. 2022;21(8):864\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"2568_CR48","doi-asserted-by":"publisher","first-page":"2813","DOI":"10.1080\/09546634.2022.2081655","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Tommasino N, Potestio L, et al. Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study. J Dermatolog Treat. 2022;33(6):2813\u201320.","journal-title":"J Dermatolog Treat"},{"issue":"4","key":"2568_CR49","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15339","volume":"35","author":"A Michelucci","year":"2022","unstructured":"Michelucci A, Manzo Margiotta F, Panduri S, et al. A real-life experience as a proof of guselkumab effectiveness and safety in patients with moderate to severe psoriasis. Dermatol Ther. 2022;35(4): e15339.","journal-title":"Dermatol Ther"},{"issue":"3","key":"2568_CR50","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s11096-022-01400-z","volume":"44","author":"D Medina-Catal\u00e1n","year":"2022","unstructured":"Medina-Catal\u00e1n D, Riera P, Pag\u00e8s-Puigdemont N, et al. A cohort study of guselkumab in the treatment of psoriasis refractory to previous biologic therapies: effectiveness, safety and adherence. Int J Clin Pharm. 2022;44(3):725\u201330.","journal-title":"Int J Clin Pharm"},{"key":"2568_CR51","first-page":"205","volume":"12","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Fabbrocini G, Ruggiero A. Long-term efficacy and safety of guselkumab for moderate to severe psoriasis: a 3-year real-life retrospective study. Psoriasis (Auckl). 2022;12:205\u201312.","journal-title":"Psoriasis (Auckl)"},{"issue":"2","key":"2568_CR52","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1080\/09546634.2020.1800577","volume":"33","author":"M Megna","year":"2022","unstructured":"Megna M, Fabbrocini G, Cinelli E, Camela E, Ruggiero A. Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience. J Dermatolog Treat. 2022;33(2):1074\u20138.","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"2568_CR53","first-page":"406","volume":"25","author":"G Malara","year":"2021","unstructured":"Malara G, Trifir\u00f2 C, Bartolotta A, et al. Real-world effectiveness and safety of guselkumab for the treatment of psoriasis: a 6-month prospective study in a series of psoriatic patients. Eur Rev Med Pharmacol Sci. 2021;25(1):406\u201312.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6","key":"2568_CR54","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1177\/1203475420932514","volume":"24","author":"K Maliyar","year":"2020","unstructured":"Maliyar K, O\u2019Toole A, Gooderham MJ. Long-term single center experience in treating plaque psoriasis with guselkumab. J Cutan Med Surg. 2020;24(6):588\u201395.","journal-title":"J Cutan Med Surg"},{"issue":"7","key":"2568_CR55","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.3390\/jcm9072170","volume":"9","author":"M Galluzzo","year":"2020","unstructured":"Galluzzo M, Tofani L, Lombardo P, et al. Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study. J Clin Med. 2020;9(7):2170.","journal-title":"J Clin Med"},{"issue":"3","key":"2568_CR56","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1080\/14712598.2022.1988566","volume":"22","author":"M Galluzzo","year":"2022","unstructured":"Galluzzo M, Chiricozzi A, Cinotti E, et al. Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. Expert Opin Biol Ther. 2022;22(3):367\u201376.","journal-title":"Expert Opin Biol Ther"},{"issue":"10091","key":"2568_CR57","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/S0140-6736(17)31279-5","volume":"390","author":"K Reich","year":"2017","unstructured":"Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390(10091):276\u201388.","journal-title":"Lancet"},{"issue":"10","key":"2568_CR58","doi-asserted-by":"publisher","first-page":"e350","DOI":"10.1111\/jdv.15643","volume":"33","author":"M Gooderham","year":"2019","unstructured":"Gooderham M, Elewski BE, Pariser DM, et al. Incidence of serious gastrointestinal events among tildrakizumab-treated patients with psoriasis: letter to the editor. J Eur Acad Dermatol Venereol. 2019;33(10):e350\u20132.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"2568_CR59","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1111\/bjd.16724","volume":"179","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Reich K, Papp KA, et al. Safety of tildrakizumab for moderate-to-severe plaque psoriasis: pooled analysis of three randomized controlled trials. Br J Dermatol. 2018;179(3):615\u201322.","journal-title":"Br J Dermatol"},{"issue":"3","key":"2568_CR60","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/bjd.18232","volume":"182","author":"K Reich","year":"2020","unstructured":"Reich K, Warren RB, Iversen L, et al. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. Br J Dermatol. 2020;182(3):605\u201317.","journal-title":"Br J Dermatol"},{"issue":"2","key":"2568_CR61","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/bjd.19866","volume":"185","author":"D Tha\u00e7i","year":"2021","unstructured":"Tha\u00e7i D, Piaserico S, Warren RB, et al. Five-year efficacy and safety of tildrakizumab in patients with moderate-to-severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2). Br J Dermatol. 2021;185(2):323\u201334.","journal-title":"Br J Dermatol"},{"issue":"10","key":"2568_CR62","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1007\/s13555-022-00793-z","volume":"12","author":"D Tha\u00e7i","year":"2022","unstructured":"Tha\u00e7i D, Gerdes S, Du Jardin KG, Perrot JL, Puig L. Efficacy of tildrakizumab across different body weights in moderate-to-severe psoriasis over 5 years: pooled analyses from the reSURFACE pivotal studies. Dermatol Ther (Heidelb). 2022;12(10):2325\u201341.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"2568_CR63","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1111\/jdv.18167","volume":"36","author":"AP Fernandez","year":"2022","unstructured":"Fernandez AP, Dauden E, Gerdes S, et al. Tildrakizumab efficacy and safety in patients with psoriasis and concomitant metabolic syndrome: post hoc analysis of 5-year data from reSURFACE 1 and reSURFACE 2. J Eur Acad Dermatol Venereol. 2022;36(10):1774\u201383.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"11","key":"2568_CR64","doi-asserted-by":"publisher","first-page":"e709","DOI":"10.1111\/jdv.17427","volume":"35","author":"D Tha\u00e7i","year":"2021","unstructured":"Tha\u00e7i D, Jullien D, Egeberg A, et al. Low incidence rate of respiratory and viral infections over 5 years of treatment with tildrakizumab in patients with moderate-to-severe psoriasis: pooled analysis from reSURFACE 1 and reSURFACE 2 phase 3 trials. J Eur Acad Dermatol Venereol. 2021;35(11):e709\u201311.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2568_CR65","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1111\/jdv.15866","volume":"34","author":"R Bissonnette","year":"2020","unstructured":"Bissonnette R, Fern\u00e1ndez-Pe\u00f1as P, Puig L, Mendelsohn AM, Rozzo SJ, Menter A. Incidence of cardiovascular events among tildrakizumab-treated patients with moderate-to-severe plaque psoriasis: pooled data from three large randomised clinical trials. J Eur Acad Dermatol Venereol. 2020;34(1):e21\u20134.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"2568_CR66","doi-asserted-by":"publisher","first-page":"703","DOI":"10.36849\/JDD.2020.5337","volume":"19","author":"MA Menter","year":"2020","unstructured":"Menter MA, Mehta NN, Lebwohl MG, et al. The effect of tildrakizumab on cardiometabolic risk factors in psoriasis by metabolic syndrome status: post hoc analysis of two phase 3 trials (ReSURFACE 1 and ReSURFACE 2). J Drugs Dermatol. 2020;19(8):703\u20138.","journal-title":"J Drugs Dermatol"},{"key":"2568_CR67","first-page":"2","volume":"9","author":"M Augustin","year":"2021","unstructured":"Augustin M, Tha\u00e7i D, Pinter A, Reich K, Lambert J, van de Kerkhof P. Long-term efficacy and safety of tildrakizumab: 5-year results from the reSURFACE 1 and 2 phase III trials in patients with moderate-to-severe plaque psoriasis. EMJ Dermatol. 2021;9:2\u201311.","journal-title":"EMJ Dermatol"},{"issue":"6","key":"2568_CR68","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/1346-8138.15763","volume":"48","author":"S Imafuku","year":"2021","unstructured":"Imafuku S, Nakagawa H, Igarashi A, et al. Long-term efficacy and safety of tildrakizumab in Japanese patients with moderate to severe plaque psoriasis: results from a 5-year extension of a phase 3 study (reSURFACE 1). J Dermatol. 2021;48(6):844\u201352.","journal-title":"J Dermatol"},{"issue":"1","key":"2568_CR69","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1111\/jdv.18572","volume":"37","author":"A Tsianakas","year":"2022","unstructured":"Tsianakas A, Schwichtenberg U, Pierchalla P, Hinz T, Diemert S, Korge B. Real-world effectiveness and safety of tildrakizumab in long-term treatment of plaque psoriasis: results from the non-interventional, prospective, multicentre study TILOT. J Eur Acad Dermatol Venereol. 2022;37(1):85\u201392.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"2568_CR70","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1111\/jdv.18594","volume":"37","author":"A Narcisi","year":"2022","unstructured":"Narcisi A, Valenti M, Gargiulo L, et al. Real-life effectiveness of tildrakizumab in chronic plaque psoriasis: a 52-week multicentre retrospective study-IL PSO (Italian landscape psoriasis). J Eur Acad Dermatol Venereol. 2022;37(1):93\u2013103.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"2568_CR71","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1159\/000519924","volume":"238","author":"KA Drerup","year":"2022","unstructured":"Drerup KA, Seemann C, Gerdes S, Mrowietz U. Effective and safe treatment of psoriatic disease with the anti-IL-23p19 biologic tildrakizumab: results of a real-world prospective cohort study in nonselected patients. Dermatology. 2022;238(4):615\u20139.","journal-title":"Dermatology"},{"issue":"10","key":"2568_CR72","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1007\/s13555-022-00800-3","volume":"12","author":"G Becher","year":"2022","unstructured":"Becher G, Conner S, Ingram JA, et al. A retrospective real-world study of the effectiveness and tolerability of tildrakizumab in UK adults with moderate-to-severe chronic plaque psoriasis. Dermatol Ther (Heidelb). 2022;12(10):2343\u201354.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"2568_CR73","volume":"35","author":"G Caldarola","year":"2022","unstructured":"Caldarola G, Galluzzo M, Bernardini N, et al. Tildrakizumab in moderate-to-severe plaque psoriasis: a multicenter, retrospective, real-life study. Dermatol Ther. 2022;35(6):e15488.","journal-title":"Dermatol Ther"},{"key":"2568_CR74","first-page":"1","volume":"10","author":"M Burlando","year":"2021","unstructured":"Burlando M, Castelli R, Cozzani E, Parodi A. Treatment of moderate-to-severe plaque psoriasis with tildrakizumab in the real-life setting. Drugs Context. 2021;10:1\u20134.","journal-title":"Drugs Context"},{"issue":"10148","key":"2568_CR75","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0140-6736(18)31713-6","volume":"392","author":"KB Gordon","year":"2018","unstructured":"Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650\u201361.","journal-title":"Lancet"},{"issue":"10198","key":"2568_CR76","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1016\/S0140-6736(19)30952-3","volume":"394","author":"K Reich","year":"2019","unstructured":"Reich K, Gooderham M, Tha\u00e7i D, et al. Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576\u201386.","journal-title":"Lancet"},{"issue":"6","key":"2568_CR77","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/jamadermatol.2020.0723","volume":"156","author":"A Blauvelt","year":"2020","unstructured":"Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649\u201358.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"2568_CR78","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjd.19341","volume":"184","author":"RB Warren","year":"2021","unstructured":"Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50\u20139.","journal-title":"Br J Dermatol"},{"issue":"8","key":"2568_CR79","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/1346-8138.14941","volume":"46","author":"M Ohtsuki","year":"2019","unstructured":"Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM phase 2\/3 trial. J Dermatol. 2019;46(8):686\u201394.","journal-title":"J Dermatol"},{"issue":"6","key":"2568_CR80","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/bjd.20595","volume":"185","author":"KA Papp","year":"2021","unstructured":"Papp KA, Lebwohl MG, Puig L, et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021;185(6):1135\u201345.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2568_CR81","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s13555-021-00556-2","volume":"11","author":"S Gkalpakiotis","year":"2021","unstructured":"Gkalpakiotis S, Cetkovska P, Arenberger P, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: real-life multicenter experience from the Czech Republic. Dermatol Ther (Heidelb). 2021;11(4):1345\u201355.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"2568_CR82","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1007\/s13555-022-00795-x","volume":"12","author":"L Gargiulo","year":"2022","unstructured":"Gargiulo L, Ibba L, Pavia G, et al. Real-life effectiveness and safety of risankizumab in 131 patients affected by moderate-to-severe plaque psoriasis: a 52-week retrospective study. Dermatol Ther (Heidelb). 2022;12(10):2309\u201324.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"6","key":"2568_CR83","volume":"35","author":"G Caldarola","year":"2022","unstructured":"Caldarola G, Zangrilli A, Bernardini N, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: a multicenter, retrospective, 1 year real-life study. Dermatol Ther. 2022;35(6):e15489.","journal-title":"Dermatol Ther"},{"issue":"7","key":"2568_CR84","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15524","volume":"35","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Ruggiero A, Camela E, Fabbrocini G. Risankizumab treatment in psoriasis patients who failed anti-IL17: a 52-week real-life study. Dermatol Ther. 2022;35(7):e15524.","journal-title":"Dermatol Ther"},{"issue":"11","key":"2568_CR85","doi-asserted-by":"publisher","first-page":"adv00605","DOI":"10.2340\/actadv.v101.283","volume":"101","author":"RG Borroni","year":"2021","unstructured":"Borroni RG, Malagoli P, Gargiulo L, et al. Real-life effectiveness and safety of risankizumab in moderate-to-severe plaque psoriasis: a 40-week multicentric retrospective study. Acta Derm Venereol. 2021;101(11):adv00605.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"2568_CR86","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jaad.2018.06.057","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: psoriasis comorbidities and preferred systemic agents. J Am Acad Dermatol. 2019;80(1):27\u201340.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"2568_CR87","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jaad.2018.06.056","volume":"80","author":"SB Kaushik","year":"2019","unstructured":"Kaushik SB, Lebwohl MG. Psoriasis: which therapy for which patient: focus on special populations and chronic infections. J Am Acad Dermatol. 2019;80(1):43\u201353.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"2568_CR88","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1111\/jdv.15653","volume":"33","author":"JJ Crowley","year":"2019","unstructured":"Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33(9):1676\u201384.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2568_CR89","doi-asserted-by":"publisher","first-page":"adv00821","DOI":"10.2340\/actadv.v102.1982","volume":"102","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Dapavo P, Trunfio M, et al. Risk of reactivation of latent tuberculosis in psoriasis patients on biologic therapies: a retrospective cohort from a tertiary care centre in northern Italy. Acta Derm Venereol. 2022;102:adv00821.","journal-title":"Acta Derm Venereol"},{"issue":"12","key":"2568_CR90","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1111\/ced.15336","volume":"47","author":"A Ruggiero","year":"2022","unstructured":"Ruggiero A, Martora F, Picone V, et al. The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience. Clin Exp Dermatol. 2022;47(12):2280\u20132.","journal-title":"Clin Exp Dermatol"},{"issue":"2","key":"2568_CR91","first-page":"99","volume":"30","author":"AM Ka\u0161nar","year":"2022","unstructured":"Ka\u0161nar AM, Juri\u0107 K, Frani\u0107 A, \u010ceovi\u0107 R. Current knowledge on psoriasis during the Covid-19 pandemic. Acta Dermatovenerol Croat. 2022;30(2):99\u2013105.","journal-title":"Acta Dermatovenerol Croat"},{"issue":"12","key":"2568_CR92","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1080\/14712598.2022.2113872","volume":"22","author":"E Camela","year":"2022","unstructured":"Camela E, Potestio L, Fabbrocini G, Ruggiero A, Megna M. New frontiers in personalized medicine in psoriasis. Expert Opin Biol Ther. 2022;22(12):1431\u20133.","journal-title":"Expert Opin Biol Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02568-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02568-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02568-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,10]],"date-time":"2023-07-10T04:16:19Z","timestamp":1688962579000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02568-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,18]]},"references-count":92,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["2568"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02568-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,18]]},"assertion":[{"value":"7 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}